Ovarian Cancer Diagnosed During Pregnancy: Treatment Methods and Coagulation Abnormalities

被引:1
作者
Ahmed Bilal
Sarfraz Ahmad
机构
[1] AdventHealth Cancer Institute,Department of Gynecologic Oncology
[2] New York University,College of Arts & Sciences
[3] Florida State University,undefined
[4] College of Medicine,undefined
[5] University of Central Florida,undefined
[6] College of Medicine,undefined
关键词
Ovarian cancer; Pregnancy; Diagnostic tests; Treatment options; Coagulation; Clinical outcomes;
D O I
10.1007/s42399-021-01022-y
中图分类号
学科分类号
摘要
Malignant tumors affect ~6% of ovarian cancer (OC) patients in early-to-mid-stage pregnancies. Studies reveal that through sessions of ultrasound during pregnancy, early diagnosis and containment become a possibility. Review of primary case studies of patients with OC during pregnancy (both first-time pregnancy and history of miscarriage) suggests that the primary end-goal for the mother is to protect the baby first and foremost. Due to this, the treatment program is designed to cater specific patient’s needs. Yet, on the basis of outcomes of studies, there are three significant treatment/management possibilities which have had successful track record: surgery, systemic chemotherapy/radiotherapy, and chemotherapeutic medications. Coagulation abnormalities in OC patients diagnosed during pregnancies are manifested by a low-grade form of disseminated intravascular coagulation. Such complications may particularly result in damage to the fetus and to the mother also. OC has one of the highest incidence rates of thrombotic events, and hypercoagulability/thrombophilia is a common indicator. Factors that contribute to the activation of coagulation in OC primarily include non-specific mechanisms such as tissue damage, inflammatory responses, and prolonged immobilization, especially during hospitalization. This minireview attempts to provide information on clinical studies which uncover specific treatment procedures in patients with OC compounded by pregnancy.
引用
收藏
页码:2260 / 2268
页数:8
相关论文
共 333 条
[1]  
Abdol Razak NB(2018)Cancer-associated thrombosis: An overview of mechanisms, risk factors, and treatment Cancers (Basel) 10 380-248
[2]  
Jones G(1992)Hemostatic alterations in cancer patients Cancer Metastasis Rev 11 237-824
[3]  
Bhandari M(2000)Effect of low-molecular-weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: a prospective randomized double-blind trial Int J Oncol 16 815-437
[4]  
Berndt MC(1992)Prognostic significance of blood coagulation tests in carcinoma of the lung and colon Blood Coagul Fibrinolysis 3 429-291
[5]  
Metharom P(1999)Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: risk analysis using Medicare claims data Medicine (Baltimore) 78 285-111
[6]  
Rickles FR(2000)Venous thromboembolism and cancer N Engl J Med 343 1338-388
[7]  
Levine M(2003)Cancer-associated thrombosis N Engl J Med 349 109-1262
[8]  
Edwards RL(2003)Venous thrombosis in cancer patients: Insights from the FRONTLINE survey Oncologist. 8 381-1948
[9]  
von Tempelhoff GF(2004)Thrombosis and cancer: implications beyond Trousseau J Thromb Haemost 2 1261-33
[10]  
Harenberg J(2004)Low-molecular-weight heparin therapy with dalteparin and survival in advanced cancer: the Fragmin Advanced Malignancy Outcome Study (FAMOUS) J Clin Oncol 22 1944-491